SureTrader SureTrader SureTrader
Home > Boards > US OTC > Medical - Drugs >

Entest BioMedical Inc. (ENTB)

Add ENTB Price Alert      Hide Sticky   Hide Intro
Moderator: sizzleweed
Search This Board:
Last Post: 1/12/2017 12:42:58 PM - Followers: 445 - Board type: Free - Posts Today: 0

                                     ENTB LATEST NEWS FROM JUNE 1, 2016:






Company Information:                                                      
4700 Spring Street, Suite 304
La Mesa, Calif. 91942
Telephone: 619-644-3344
Fax: 619-330-2328
[email protected]

Web site:


CIK 0001449447

ImenVax (TM)

Immuno-Therapeutic Cancer Treatment for Canines


In the encapsulated ImenVax™ device, a "cocktail" of integral immuno-catalysts are enclosed. From this ImenVax™ device immuno-catalysts are released which activate the patient's immune cell. These immune cells carry on their normal course of activity by entering the lymph nodes and cause T-Cell adaptation. These T-Cells are what attack and kill the tumor. (Figure 1)

Entest BioMedical Inc. (OTCQB: ENTB)is a majority owned subsidiary of Bio-Matrix Scientific Group Inc (OTCQB: BMSN). The Company is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), cancer immuno-therapies, testing procedures for diabetes and stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation).

Currently, Entest is focused on research and development in areas of COPD and Immuno-Therapeutic Cancer Vaccines. The Company sees applications for its patent pending technologies in both human and animal venues.

Immuno-therapeutic treatment of cancer - The patent pending Entest application involves perfecting the use of cell lines for sustained release of immunologically relevant cytokines for maximum anti-tumor immune responses in treating cancer. The treatment process itself will utilize an implantable encapsulation device as the vaccine delivery system and the initial focus will be treatment of cancer in canines. This canine cancer treatment may also provide clinical support for expansion into human cancer treatment.

Chronic Obstructive Pulmonary Disease -There is currently no cure for COPD and therapy is limited to management of the condition and its symptoms. Over the next 5 years, it is estimated that over $170 billion will be spent on treating COPD in the United States. Entest believes its COPD treatment, which utilizes patent pending adult stem cell therapy coupled with photoceutical device enhancement, has the potential to reverse COPD related lung damage as well as alleviate symptoms.

Entest BioMedical was founded for the purpose of providing excellence in biotechnology research (including adult stem cell regenerative treatment). Our objectives go beyond developing single products and procedures. Our mission is to discover and develop new procedures, treatments and medical devices that improve the quality of life. Our efforts revolve around a business focus of developing leading research and technology. Ongoing R&D is paramount to us in developing products and procedures with purpose, products and services that serve the present and help shape the future.



David R. Koos, PhD, DBA - Chairman and CEO, Secretary, Acting CFO
Feng Lin, MD, PhD - Director of Research
Marilyn Panahi - Director of Quality Assurance

 Recent News!

June 1, 2015




  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
ENTB News: Quarterly Report (10-q) 01/11/2017 10:29:57 AM
ENTB News: Annual Report (10-k) 11/23/2016 06:08:21 AM
ENTB News: Current Report Filing (8-k) 09/26/2016 06:04:39 AM
#37750  Sticky Note sizzleweed 06/25/16 03:12:29 AM
#37951   Top 10 animal health companies that could be JokersWild12 01/12/17 12:42:58 PM
#37950   Wow, really we are all doomed here just jhenmal 01/11/17 06:25:31 PM
#37949   Well I am sure it applies to message gotinearly 01/11/17 04:45:12 PM
#37948   just thinking out loud, does anybody know if jhenmal 01/11/17 03:45:56 PM
#37947   LOCK HIM UP, LOCK HIM UP, LOCK HIM UP jhenmal 01/11/17 06:53:54 AM
#37946   Crocs, Hopefully that doesn't happen. Indeed there will be JokersWild12 01/10/17 03:54:13 PM
#37945   the negative that I see here is the Crocs69 01/10/17 02:48:24 PM
#37944   Thx Kbro, absolutely thrilled to see that Rk3 01/10/17 02:40:17 PM
#37943   This could be a very aggressive move. I salesleader 01/10/17 02:20:48 PM
#37942   Thanks Kbro, JokersWild12 01/10/17 11:11:29 AM
#37941   NEWS Kbro13 01/10/17 09:39:08 AM
#37940   Watch for an orchestrated drop in share price gotinearly 01/09/17 10:16:24 AM
#37939   That's an older video but Entest(ENTB) is pursuing JokersWild12 12/31/16 12:52:27 PM
#37938 jhenmal 12/29/16 05:36:15 PM
#37937   I'm only entb but lookie here , it salesleader 12/22/16 11:32:17 AM
#37936   I agree with you. I'm holding on to psk3091 12/22/16 11:22:33 AM
#37935   I'm right here with you and Joker, February salesleader 12/22/16 10:58:18 AM
#37934   In the RGBP 10K, Kood refers for shares ctvette2003 12/21/16 05:25:03 PM
#37933   Thanks for the hint, Koos jeffshir 12/21/16 03:27:15 PM
#37932   Always thought the veterinary route would profit first jeffshir 12/21/16 03:19:36 PM
#37931   JW12: Thanks for a reply. So, let's all psk3091 12/21/16 01:30:59 PM
#37930   PSK, I have been here equally as long JokersWild12 12/21/16 01:18:30 PM
#37929   Quote from the PR From 12/21/16 ENTB PR: psk3091 12/21/16 12:50:53 PM
#37928   Great to see a PR for ENTB and JokersWild12 12/21/16 12:22:11 PM
#37927   Entest BioMedical, Inc. Chairman David Koos Discusses Zander angel38 12/21/16 11:32:03 AM
#37926   I think Koos will make these companies grow salesleader 12/19/16 01:01:34 PM
#37925   Nice find SL, The Journal Transcript article from JokersWild12 12/19/16 11:18:19 AM
#37924   Someone is trying to get the word out salesleader 12/19/16 10:41:43 AM
#37923   $4.00 trade to knock ENTB down.Market Managers only ronrooster 12/15/16 04:57:30 PM
#37922   I keep thinking it actually might be coming salesleader 12/14/16 05:28:36 PM
#37921   Look out!! Could be another strong day for tru2u2 12/12/16 09:20:17 AM
#37920   I think its last news is in part stockseekerok 12/12/16 07:53:41 AM
#37919   Thanks, SSO. Entest BioMed is making healthy gains. TKane 12/12/16 07:47:04 AM
#37918   Also,ENTB float is under 17 million.o/s 40 m-8 ronrooster 12/10/16 07:19:00 PM
#37917   Good to see u back on the ENTB ronrooster 12/10/16 10:39:26 AM
#37916   ENTB any idea what percentage of ENTB is sizzleweed 12/09/16 09:33:57 PM
#37915   Rooster, that's a he++ no on an IPO. JokersWild12 12/09/16 01:01:24 PM
#37914   I am holding ENTB long term as well. ronrooster 12/09/16 12:17:19 PM
#37913   I've been in this stock over 2 years, salesleader 12/08/16 05:43:55 PM
#37912   Wow! Insane amount of chatter but 3 Kbro13 12/08/16 04:22:15 PM
#37911   The company has put out some interesting news zigzagman 12/08/16 03:49:01 PM
#37910   Their site getting big buzz! budfoxhub 12/08/16 03:41:08 PM
#37909   Good to see's opinion on the chart zigzagman 12/08/16 02:46:52 PM
#37908   Stock getting big buzz! budfoxhub 12/08/16 02:40:43 PM
#37907   $ENTB is a BUY Barchart Technical Opinion easymoneylucy 12/08/16 02:40:41 PM
#37906   I think we will see a push during Cabroncita 12/08/16 02:39:18 PM
#37905   ENTB trending higher. I like it Robertscott 12/08/16 02:31:07 PM
#37904   Any kind of Volume could get this one zigzagman 12/08/16 02:28:23 PM
#37903   Ready for a power hour push! budfoxhub 12/08/16 02:16:41 PM
#37902   I found this article about NR2F6 on the zigzagman 12/08/16 01:54:17 PM